- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05238376
Survivorship Post-HCT Optimization Program (S-POP)
September 25, 2025 updated by: Duke University
The Effect of High-intensity Interval Training (HIIT) and Resistance Training on Function, Health, and Quality of Life Outcomes Following Hematopoietic Stem Cell Transplant
The purpose of this project is to investigate the effects of 12 weeks of high-intensity interval training (HIIT) and resistance training on several domains of health including physical function, cognitive function, mental health, and quality of life in patients who have undergone hematopoietic stem cell transplant (HCT).
In addition, the project will determine the effects of 12 weeks of HIIT and resistance training on physical function, caregiver strain, mental health, and caregiver confidence in individuals who are providing care for patients undergoing HCT.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
16
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Duke Adult Blood and Marrow Transplant Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 76 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Patient Inclusion Criteria:
- ≥18 years old
- English speaking
- Within 90 ± 30 days post allogenic HCT
Caregiver Inclusion Criteria:
- ≥18 years old
- English speaking
- Providing post-discharge care for the patient who has undergone HCT
Patient and Caregiver Exclusion Criteria:
- Have an absolute contraindication to exercise including a recent acute cardiac event (<6 months), unstable angina, uncontrolled dysthymias causing symptoms or hemodynamic compromise, symptomatic aortic stenosis, uncontrolled symptomatic heart failure, acute pulmonary embolus, acute myocarditis or pericarditis, suspects or known dissecting aneurism, or coronary artery disease.
- In addition to these absolute contraindications, the patient and caregiver will complete cardiopulmonary exercise testing (CPET) where the heart rate and heart rhythm will be monitored via a 12-lead ECG before, during, and after the test. The results from the CPET will be reviewed by a physician before the subject is cleared to participate in the HIIT and resistance training program. If the participant is not cleared by the physician following the CPET, then the patient and his or her caregiver will not be eligible to participate in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Patient
These are patients who are 90 (±30) days post-allogeneic hematopoietic stem cell transplant.
Patients will complete 12 weeks of exercise training.
Patients will also complete assessments to evaluate physical function, cognitive function, mental health, social support, nutrition and diet, symptoms, quality of life, and financial status.
They will use devices to capture activity data and vital signs.
They will collect bio-specimens to assess microbiota and biomarkers.
|
12 weeks of high intensity interval training (HIIT) (3x/week) and resistance training (2x/week)
|
|
Experimental: Caregiver
These are the assigned caregivers for the transplant patients.
Caregivers will complete 12 weeks of exercise training.
Caregivers will also complete assessments to evaluate physical function, caregiver support, and physical activity and exercise.
They will collect bio-specimens to assess microbiota.
|
12 weeks of high intensity interval training (HIIT) (3x/week) and resistance training (2x/week)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Adherence to prescribed exercise program, as measured by number of total sessions completed
Time Frame: 12 weeks
|
12 weeks
|
|
Compliance to prescribed HIIT sessions, as measured by total session time (in minutes)
Time Frame: 12 weeks
|
12 weeks
|
|
Compliance to prescribed HIIT sessions, as measured by number of intervals completed
Time Frame: 12 weeks
|
12 weeks
|
|
Compliance to prescribed HIIT sessions, as measured by number/percentage of intervals meeting target heart rates
Time Frame: 12 weeks
|
12 weeks
|
|
Compliance to prescribed resistance sessions, as measured by number of sets completed
Time Frame: 12 weeks
|
12 weeks
|
|
Compliance to prescribed resistance sessions, as measured by number of repetitions completed
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in physical function/activity, as measured by SPPB
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
All the task points are added which make the SPPB score.
The cut-point for the SPPB is a score of 10.
The cumulative and sections scores are assessed individually and comprehensively.
This assessment score will be used as a tool for evaluating lower extremity functioning in older persons.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in physical function/activity, as measured by 6-minute walk test
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
The baseline for each patient is made through an algorithm that factors the patients age and gender.
The patient's score is compared to what a person that is the patient's same age and gender would get.
This comparison is then used as a tool to assess aerobic capacity or endurance.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in physical function/activity, as measured by 30-second sit-to-stand
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
Subjects will sit in a chair with their arms crossed over their chest and rise to a standing position, then return to seated position.
They will repeat this as many times as they can in 30 seconds.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in physical function/activity, as measured by grip strength
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
The hand grip is an indicator of upper body strength and has been found to be a good predictor of future functional limitations and disabilities.
The hand grip score is determined based on how quickly the participant can squeeze the hand dynamometer.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in physical function/activity, as measured by Fried Frailty
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
The scores of all of the sections are added and if the patient has a score greater or equal to three this assessment deems that the patients is frail.
If the patient has a score between 1-2 the patient is deemed pre-frail.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in physical function/activity, as measured by PROMIS Physical Function
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
The questions are asked as interval format with "0-Never" through "5-Always."
Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in physical function/activity, as measured by bioelectrical impedance (BIA)
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
Participants will have body composition assessed by bioelectrical impedance spectroscopy (BIS) via a bioimpedance analysis (BIA) device.
BIA equipment does not measure muscle mass directly, but instead derives an estimate of muscle mass based on whole-body electrical conductivity.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in physical function/activity, as measured by CPET
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
Exercise capacity will be assessed using a symptom-limited Cardiopulmonary Exercise Test (CPET) on a cycle ergometer or for a six-minute step test with expired gas analysis to determine VO2peak, according to guidelines for clinical populations (Jones et al., 2012).
All CPET data will be recorded as the highest 30-second value elicited during the CPET.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in physical function/activity, as measured by Intramuscular Adipose Tissue (IMAT)
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
Longitudinal and transverse ultrasound images of the m.
rectus femoris, vastus lateralis, m. intercostalis / m. pectoralis, (head) m. temporalis, and/or (head) styloglossus.
Complex grayscale analysis of the images is used to calculate the IMAT.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in physical function/activity, as measured by Intramuscular Glycogen Content (IMGC)
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
Longitudinal and transverse ultrasound images of the m.
rectus femoris, vastus lateralis, m. intercostalis / m. pectoralis, (head) m. temporalis, and/or (head) styloglossus.
Complex grayscale analysis of the images is used to calculate the IMGC.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in physical function/activity, as measured by muscle thickness
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
Longitudinal and transverse ultrasound images of the m.
rectus femoris, vastus lateralis, m. intercostalis / m. pectoralis, (head) m. temporalis, and/or (head) styloglossus, using greyscale analyses.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in physical function/activity, as measured by muscle area
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
Longitudinal and transverse ultrasound images of the m.
rectus femoris, vastus lateralis, m. intercostalis / m. pectoralis, (head) m. temporalis, and/or (head) styloglossus, using greyscale analyses.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in physical function/activity, as measured by subcutaneous fat layer thickness
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
Longitudinal and transverse ultrasound images of the m.
rectus femoris, vastus lateralis, m. intercostalis / m. pectoralis, (head) m. temporalis, and/or (head) styloglossus, using greyscale analyses.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in cognitive function, as measured by Montreal Cognitive Assessment (MOCA)
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
This administered assessment is subdivided into visuospatial/executive (5pts), naming (3pts), memory (no points), attention(5pts), language(3pts), abstraction(2pts), delayed recall(5pts), and orientation(6pts).
All the subdivided sections have as many questions as they have points.
For analysis, the cut point is if the patient has less than 26 points.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in cognitive function, as measured by PROMIS Cognitive Function
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
The questions are asked as interval format with "0-Never" through "5-Always."
Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in cognitive function, as measured by RBANS
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
RBANS evaluation produces five index scores as well as a total summary score, and total scaled score.
Scores range from 40 to 160, with higher scores indicating better performance (Smith et al., 2014).
The scaled score classifies neuropsychological performance as: extremely low (69 and below), borderline (70-79), low average (80-89), average (90-109), high average (110-119), superior (120-129), and very superior (130 and above) (Batty et al., 2016; Randolph et al., 1998).
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in cognitive function, as measured by Trail making test
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
Trail Making Test parts A and B (TMT-A and -B) will be used for identification of cognitively impairment.
Total time to completion will be used as outcome variable for both parts (ranging from 0 to 300 seconds, with higher scores indicating worse performance (Smith et al., 2014).
An adjusted mean T-score also will be calculated ranging from 0 to 100 (mean score 50, higher score indicating better performance).
The T-score can be adjusted for age, sex, education and ethnicity.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in cognitive function, as measured by Brief Cope
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
Scores are presented for three overarching coping styles as average scores (sum of item scores divided by number of items), indicating the degree to which the respondent has been engaging in that coping style.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in mental health, as measured by PHQ-9
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
The PHQ-9 consists of 9 items, each of which is scored 0 to 3, giving a 0 to 27 severity score
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in mental health, as measured by PC-PTSD/PCL-5
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
PC-PTSD is a 5 item screen to identify patients with probable PTSD.
If the patient screens positive, they then take the PCL-5.
The PCL-5 is a 20 item screen to assess symptoms of PTSD.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in mental health, as measured by PROMIS Depression
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
The questions are asked as interval format with "0-Never" through "5-Always."
Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in mental health, as measured by PROMIS Anxiety
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
The questions are asked as interval format with "0-Never" through "5-Always."
Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in diet/nutrition, as measured by Perioperative Nutrition Screen (PONS)
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
PONS analyzes BMI, weight loss, and food intake to screen for preoperative nutrition risk
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in diet/nutrition, as measured by PG-SGA/Clinician SGA
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
Scores for each section can range from 0-4 depending on severity and nutritional impact.
The sum of all scores provides the Total PG-SGA score, which can be used to indicate the need for intervention (Bauer et al., 2002)
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in diet/nutrition, as measured by ASA-24
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
ASA-24 is a self-administered 24-hour diet recall
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in diet/nutrition, as measured by Food Security
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
Participants will be given the USDA food security survey to review their food securities or insecurities.
This is a 10 item survey.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in social support, as measured by PROMIS Emotional Support
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
The questions are asked as interval format with "0-Never" through "5-Always."
Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in social support, as measured by PROMIS Social Isolation
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
The questions are asked as interval format with "0-Never" through "5-Always."
Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in social support, as measured by Lorig Self Efficacy
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
The Self-Efficacy to Manage Chronic Disease Scale is made up of 6-items on a visual analog scale, ranging from 1 (not at all confident) to 10 (totally confident).
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in social support, as measured by CFC-14
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
CFC-14 is a 14 item questionnaire to assess a patient's consideration of immediate and consideration of future consequences
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in social support, as measured by Brief Resilience Scale
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
BRS assesses the patient's ability to recover from stress.
The possible score range on the BRS is from 1 (low resilience) to 5 (high resilience).
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in caregiver support, as measured by Caregiver Strain index
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
Tool to assess strain on long-term caregivers
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in caregiver support, as measured by Preparedness for Caregiving assessment
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
Items are scored by calculating the mean of all items with a range of 0-4.
The higher the score, the more prepared the caregiver feels to give care.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in caregiver support, as measured by FACT-GP
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
21 item assessment scored on a 5-point Likert scale
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in caregiver support, as measured by PHQ-2
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
The PHQ-9 consists of 2 items, each of which is scored 0 to 3, giving a 0 to 6 severity score
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in caregiver support, as measured by PCL-5
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
The PCL-5 is a 20 item screen to assess symptoms of PTSD.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in caregiver support, as measured by Ego Resiliency
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
14 item survey scored from 0-56, where a higher score indicates higher level of resiliency
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in caregiver support, as measured by PROMIS Depression
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
The questions are asked as interval format with "0-Never" through "5-Always."
Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in caregiver support, as measured by PROMIS Anxiety
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
The questions are asked as interval format with "0-Never" through "5-Always."
Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in caregiver support, as measured by PROMIS Emotional Support
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
The questions are asked as interval format with "0-Never" through "5-Always."
Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in caregiver support, as measured by PROMIS Social Isolation
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
The questions are asked as interval format with "0-Never" through "5-Always."
Each of the PRO instruments will be scored on the T-score metric, where 50 is the mean of a reference population and 10 is the standard deviation of that population.
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in microbiota diversity, as measured by skin swabs
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
Skin swab samples batch sequenced and microbiome analyzed
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in microbiota diversity, as measured by stool samples
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
Changes in stool samples as measured by 16s rRNA sequencing
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Change in biomarkers of inflammation and frailty, as measured by blood plasma samples
Time Frame: Baseline, Post-intervention (week 12), 1 Year
|
Assays evaluating angiogenic, stromal, and inflammatory markers and markers of aging (the Pepper Panel) are used to assess inflammation and frailty
|
Baseline, Post-intervention (week 12), 1 Year
|
|
Overall survival, as measured by medical record review
Time Frame: 1 year
|
1 year
|
|
|
Disease-free survival, as measured by medical record review
Time Frame: 1 year
|
1 year
|
|
|
Rate of bacterial infection, as measured by medical record review
Time Frame: 1 year
|
1 year
|
|
|
Rate of fungal infection, as measured by medical record review
Time Frame: 1 year
|
1 year
|
|
|
Rate of viral infection, as measured by medical record review
Time Frame: 1 year
|
1 year
|
|
|
Rate of overall infection, as measured by medical record review
Time Frame: 1 year
|
1 year
|
|
|
Rate of hospital admission, as measured by medical record review
Time Frame: 1 year
|
1 year
|
|
|
Rate of intensive care unit admission, as measured by medical record review
Time Frame: 1 year
|
1 year
|
|
|
Hospital length of stay, as measured by medical record review
Time Frame: 1 year
|
1 year
|
|
|
Intensive care unit length of stay, as measured by medical record review
Time Frame: 1 year
|
1 year
|
|
|
Number of patients with grade 2+ graft-versus-host disease, as measured by medical record review
Time Frame: 1 year
|
1 year
|
|
|
Transplant length of stay (in days), as measured by medical record review
Time Frame: 1 year
|
1 year
|
|
|
Number of patients who returned to work, as assessed by Work Assessment
Time Frame: 1 year
|
1 year
|
|
|
Number of falls, as assessed by Falls questionnaire
Time Frame: 1 year
|
Participants will answer Yes/No to whether they have had any falls in the preceding 6 months
|
1 year
|
|
Number of subjects who experienced delirium, as assessed by DOS assessment
Time Frame: 1 year
|
The Delirium Observation Screening Scale is a 13-item observational scale of verbal and nonverbal behavior.
The observations can be done during regular care.
The DOS is used to optimize recognition of delirium.
|
1 year
|
|
Change in quality of life, as assessed by FACT-BMT assessment
Time Frame: Baseline, Post-intervention (12 weeks), 1 Year
|
50 item assessment.
Higher total and domain scores indicate greater quality of life.
|
Baseline, Post-intervention (12 weeks), 1 Year
|
|
Change in quality of life, as assessed by EQ-5D-5L assessment
Time Frame: Baseline, Post-intervention (12 weeks), 1 Year
|
The 5D represents 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Five levels of severity are measured, as indicated by the "5L," ranging from "no problems" to "extreme problems."
All scores are converted into a summary index.
|
Baseline, Post-intervention (12 weeks), 1 Year
|
|
Change in quality of life, as assessed by OARS IADL assessment
Time Frame: Baseline, Post-intervention (12 weeks), 1 Year
|
OARS IADL is a 7 item assessment that asks what level of assistance is needed to do 7 different activities of daily living
|
Baseline, Post-intervention (12 weeks), 1 Year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Chenyu Lin, MD, Duke University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 2, 2022
Primary Completion (Actual)
February 26, 2025
Study Completion (Actual)
March 23, 2025
Study Registration Dates
First Submitted
February 2, 2022
First Submitted That Met QC Criteria
February 11, 2022
First Posted (Actual)
February 14, 2022
Study Record Updates
Last Update Posted (Estimated)
September 26, 2025
Last Update Submitted That Met QC Criteria
September 25, 2025
Last Verified
September 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00110028
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hematologic Malignancy
-
CRISPR Therapeutics AGEnrolling by invitationHematologic Malignancy | Solid MalignancyUnited States, Australia, Canada, Germany
-
Epizyme, Inc.WithdrawnRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
Scripps Translational Science InstituteCompleted
-
Millennium Pharmaceuticals, Inc.Completed
-
St. Jude Children's Research HospitalRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancyUnited States
-
Guardant Health, Inc.CompletedNon-Hematologic MalignancyUnited States
-
CCTU- Cancer ThemeRecruitingCancer | Non-Hematologic MalignancyUnited Kingdom
-
Century Therapeutics, Inc.RecruitingHematological Malignancy | Solid Tumor MalignancyUnited States
-
Ruijin HospitalRecruitingHematologic MalignancyChina
-
Princess Maxima Center for Pediatric OncologyRecruitingRefractory Hematologic Malignancy | Relapsed Hematologic MalignancySpain, Denmark, Netherlands, Belgium, Hungary, Sweden, United Kingdom
Clinical Trials on Exercise training
-
University of Sao PauloFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
University of British ColumbiaMichael Smith Foundation for Health ResearchCompleted
-
Universidade Norte do ParanáCompleted
-
University of Colorado, DenverVA Eastern Colorado Health Care SystemCompletedHealthy | Overweight | Type 2 Diabetes Mellitus | Cardiovascular Risk FactorUnited States
-
National Taiwan University HospitalCompletedAtrial FibrillationTaiwan
-
Universita di VeronaRecruiting
-
University of LeipzigCompletedImpact of Intensive Exercise Training on Coronary Collateral Circulation in Patients With Stable CADStable Coronary Artery DiseaseGermany
-
Helse Stavanger HFStavanger Health ResearchCompletedVentricular TachycardiaNorway
-
Hacettepe UniversityCompleted
-
Toronto Rehabilitation InstituteCompletedAcute Myeloid LeukemiaCanada